GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Turning Point Therapeutics Inc (NAS:TPTX) » Definitions » Goodwill

Turning Point Therapeutics (Turning Point Therapeutics) Goodwill : $0.00 Mil (As of Jun. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Turning Point Therapeutics Goodwill?

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Turning Point Therapeutics's goodwill for the quarter that ended in Jun. 2022 was $0.00 Mil.


Turning Point Therapeutics Goodwill Historical Data

The historical data trend for Turning Point Therapeutics's Goodwill can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Goodwill Chart

Turning Point Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
Goodwill
- - - - -

Turning Point Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Goodwill Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Turning Point Therapeutics Goodwill Calculation

A Goodwill is an intangible asset that arises as a result of the acquisition of one company by another for a premium value. The value of a company's brand name, solid customer base, good customer relations, good employee relations and any patents or proprietary technology represent goodwill. Goodwill is considered an intangible asset because it is not a physical asset like buildings or equipment. The goodwill account can be found in the assets portion of a company's balance sheet.


Turning Point Therapeutics  (NAS:TPTX) Goodwill Explanation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Turning Point Therapeutics's Goodwill-to-Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Goodwill-to-Asset (A: Dec. 2021 )=Goodwill/Total Assets
=0/1003.463
=0.00

Turning Point Therapeutics's Goodwill-to-Asset Ratio for the quarter that ended in Jun. 2022 is calculated as

Goodwill-to-Asset (Q: Jun. 2022 )=Goodwill/Total Assets
=0/843.335
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Turning Point Therapeutics Goodwill Related Terms

Thank you for viewing the detailed overview of Turning Point Therapeutics's Goodwill provided by GuruFocus.com. Please click on the following links to see related term pages.


Turning Point Therapeutics (Turning Point Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Turning Point Therapeutics Inc is a clinical-stage biopharmaceutical company involved in designing and developing molecule, targeted oncology therapies to address limitations of existing therapies. It owns a pipeline of next-generation tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The company's lead drug candidate, repotrectinib, is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
Executives
Paolo Tombesi officer: EVP & Chief Financial Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Steve M Sabus officer: SVP & Chief Commercial Officer 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Brian Sun officer: SVP & General Counsel C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Mohammad Hirmand officer: EVP and Chief Medical Officer C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Athena Countouriotis director, officer: President & CEO C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Siegfried Reich officer: EVP & Chief Scientific Officer 10505 ROSELLE STREET SAN DIEGO CA 92121
Andrew John Partridge officer: EVP & Chief Commercial Officer C/O CENTREXION THERAPEUTICS CORPORATION 200 STATE STREET BOSTON MA 02109
Annette North officer: EVP, General Counsel & Secty. C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Mark J Alles director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Van Hoose Kyri K. officer: Principal Accounting Officer C/O TURNING POINT THERAPEUTICS, INC., 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Barbara W. Bodem director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Brian Lee Baker officer: VP of Finance and Admin. C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Yi Larson officer: EVP & Chief Financial Officer C/O RAYZEBIO, INC., 5505 MOREHOUSE DRIVE, SUITE 300, SAN DIEGO CA 92121
Jingrong Jean Cui director, 10 percent owner, officer: Chief Scientific Officer C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DR., STE. 225 SAN DIEGO CA 92121
Simeon George director 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428

Turning Point Therapeutics (Turning Point Therapeutics) Headlines

From GuruFocus

INVESTIGATION ALERT: Halper Sadeh LLP Investigates TPTX, MANT, CDEV, CTT

By GuruFocusNews GuruFocusNews 07-04-2022